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1  | INTRODUC TION
Alzheimer's disease (AD) is a progressive neurodegenerative dis‐
ease. The World Alzheimer Report 2016 described that about 47 
million people were suffering from dementia. The pathophysiology 
of AD includes neurotransmitter deficiency, Aβ protein accumula‐
tion, neurofibrillary tangles, neuron loss and so on.1 Among these 
mechanisms, neuron loss is one of the major disease risks of AD.2 
Neuroscience research shows that the generation of newborn neu‐
rons is sustained throughout adulthood because of the proliferation 
and differentiation of adult neural stem cells. Neural stem cells in 
the subgranular zone of the hippocampus facilitate the formation 
of new neurons that migrate a short distance into the granule cell 
layer of the dentate gyrus (DG), which shows lifelong structural and 
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Abstract
Cucurbitacin B (CuB) isolated from Cucumis melo by using a PC12 cell bioassay system 
exhibited	significant	nerve	growth	factor	(NGF)‐mimic	or	NGF‐enhancing	activity	in	
PC12 and primary neuron cells. It was also demonstrated pro‐neurogenesis effects 
in	ICR	and	APP/PS1	mice	and	improved	memory	deficit	of	APP/PS1	mice.	Its	possible	
mechanism includes significant induction of the phosphorylation of glucocorticoid 
receptor (GR), protein kinase C (PKC), phospholipase C (PLC) and inhibition of cofilin. 
ChemProteoBase	 profiling,	 binding	 assay	 and	 cellular	 thermal	 shift	 assay	 (CETSA)	
were used to determine the target protein. Results revealed that CuB could affect 
actin dynamics as an actin inhibitor but did not bind with GR. The protein level of co‐
filin in PC12 cells after treating 0.3 μM	and	different	temperatures	was	significantly	
higher than that of control group. Other neurotrophic signalling pathways, such as 
TrkA/TrkB, were analysed with specific inhibitors and Western blot. The inhibitors of 
TrkA, PLC, PKC, Ras, Raf and ERK1/2 significantly decreased the percentage of PC12 
cells with neurite outgrowth and shortened the length of neurite outgrowth induced 
by CuB. CuB significantly induced the phosphorylation of TrkA, ERK and CREB. The 
phosphorylation of these proteins was obviously decreased by their specific inhibi‐
tors. These results suggest that cofilin is a candidate target protein of CuB in PC12 
cells and that the GR/PLC/PKC and TrkA/Ras/Raf/ERK signalling pathways play im‐
portant roles in the neuroprotective effect of CuB.
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functional plasticity.3 However, the survival of newborn neuronal 
cells in AD transgenic mice that exhibit Alzheimerr's‐type amyloid 
pathology is dramatically impaired. Thus, attempts to increase the 
number of newborn neuron cells in the hippocampus have been 
exerted to improve memory, which is crucial for the prevention or 
treatment of AD.4
The PC12 cell bioassay system is proven reliable in the inves‐
tigation	of	 potential	 drugs	with	nerve	 growth	 factor	 (NGF)‐mimic	
activity.5	NGF	is	a	secreted	growth	factor	that	 is	 important	 in	the	
survival, growth and maintenance of specific types of neurons in 
the	central	nervous	system	(CNS)	and	peripheral	nervous	system.6 
Similar	to	neuron	cells,	PC12	cells	cease	dividing	and	begin	to	differ‐
entiate	after	treatment	with	NGF.	However,	the	application	of	NGF	
as a drug is limited by its inability to cross the blood‐brain barrier 
(BBB).	Thus,	finding	novel	molecules	that	demonstrate	NGF‐mimic	
activity, exhibit neurogenesis function and can cross the BBB is 
important.5
Traditional	Chinese	medicines	(TCMs)	are	great	sources	of	com‐
pounds	with	medical	uses.	TCMs	include	many	potential	lead	com‐
pounds	that	display	NGF‐mimic	or	NGF‐enhancing	activity	in	PC12	
cells.5,7 Cucurbitacin B (CuB) isolated from Cucumis melo (Tiangua 
Di	 in	 Chinese)	 shows	NGF‐mimic	 activity	 in	 PC12	 cells.	 CuB	 also	
exhibits pharmacological functions, such as anti‐inflammatory, an‐
algesic and antiplasmodial activities.8,9	Furthermore,	CuB	has	been	
approved	 by	 the	 State	 Food	 and	Drug	Administration	 (SFDA)	 and	
prescribed to treat hepatitis and hepatic carcinoma. However, re‐
ports about the in vivo and in vitro neurogenesis and neuroprotec‐
tive activity of CuB are lacking.
The present study revealed the neuroprotective function of 
CuB. This function is mainly mediated by glucocorticoid receptor 
(GR) signalling pathway, and cofilin is considered as the candidate 
target. At the same time, we find that TrkA/Ras/Raf/extracellular 
signal‐regulated kinase (ERK) is also involved in the function of 
CuB.
2  | MATERIAL S AND METHODS
2.1 | Isolation and structure elucidation of CuB
Cucurbitacin	B	 (Figure	1A)	was	 isolated	 from	the	stems	of	C melo, 
and the chemical structure was determined by comparing 1H	NMR	
and 13C	 NMR	 with	 the	 reported	 literature.10 Detailed separation 
and structure elucidation steps are presented in supplementary 
materials.
2.2 | NGF‐mimic activity bioassay in PC12 cells
Normal‐type PC12 cell line was purchased from the Cell Bank of 
the	Chinese	Academy	of	Sciences	 (Shanghai,	China).	Meanwhile,	
wide‐type and Ras mutant‐type PC12 cells (RasN17) were pro‐
vided by Professor Hiroyuki Osada.11	In	NGF‐mimic	assay,	20	000	
PC12 cells were seeded in each well of a 24‐well microplate in 
1	mL	CM	medium	(Dulbeccor's	modified	Eagler's	medium	[DMEM;	
Thermo	Scientific]	containing	10%	foetal	bovine	serum,	5%	horse	
serum	 and	 1%	 pre‐mixed	 antibiotics	 [Invitrogen])	 and	 incubated	
in	5%	CO2 at 37°C. The medium was replaced after 24 hours with 
1	mL	serum‐free	DMEM	medium	containing	a	test	sample	or	0.5%	
dimethyl	 sulphoxide	 (DMSO).	 In	 the	 inhibitor	 test,	 the	 cells	 in	
24‐well microplates were pre‐cultured with 500 μL medium con‐
taining an inhibitor for 30 minutes. Then, another 500 μL medium 
containing	 a	 test	 sample	 or	 0.5%	DMSO	was	 added.	 The	 inhibi‐
tors of TrkA, ERK, GR, PLC, PKC and Ras (K252a, U0126, RU486, 
U73343,	GO6983	and	S3131)	were	obtained	from	Sigma.	The	Raf	
and TrkB inhibitors (AZ628 and ANA‐12) were purchased from 
Axon	Medchem	BV	and	Selleckchem,	respectively.	After	48	hours,	
the morphological changes in the cells were observed using a 
phase‐contrast	microscope	(Model	CKX41;	Olympus).	About	100	
cells were counted in each of three randomly chosen fields. A posi‐
tive cell was defined as the neurite outgrowth of a cell longer than 
the diameter of cell body.
2.3 | MTT assay
Cell viability was determined based on mitochondria‐dependent 
reduction of 3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyl tetrazolium 
bromide	 (MTT),	 and	 the	method	 of	MTT	 assay	was	 performed	 as	
described in other reports, and details are presented in supplemen‐
tary materials.12
2.4 | Primary cortical neuron cell culture and bioassay
The primary cortical neuron cells were obtained from the em‐
bryos of ICR mice, and NeuO was used to visualize the neuron 
cells as described in the report.13 Detailed methods for primary 
neuron cell culture and bioassay are presented in supplementary 
materials.
2.5 | ChemProteoBase profiling
ChemProteoBase profiling was performed as described in other re‐
ports.14	Briefly,	HeLa	cells	were	first	treated	with	CuB	(1	µM)	for	
18 hours. A 2‐D DIGE system (GE Healthcare) was used to per‐
form the proteome analysis of cell lysates, and images of the gels 
were	analysed	using	Progenesis	SameSpots	(Nonlinear	Dynamics).	
Out of more than 1000 spots detectable in each gel, 296 spots 
that were found in common between gels of reference compound‐
treated cells were selected. The volume of each spot was then nor‐
malized using the average of the corresponding control values from 
DMSO‐treated	HeLa	cells.	Using	the	normalized	volume	of	the	296	
spots, we calculated the cosine similarity between compounds 
and performed hierarchical clustering analysis with Gene Cluster 
3.0 (clustering method; centroid linkage with means of uncentred 
correlation).	The	predictive	dendrogram	was	visualized	using	Java	
Treeview 1.1.3.
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2.6 | Western blot
Briefly, 2 × 106 PC12 cells were seeded and cultured in a 6‐cm plate 
containing	5	mL	of	DMEM	medium	for	24	hours.	In	the	time‐depend‐
ent	 study	of	CuB,	 300	nM	CuB	was	 added	 and	 incubated	 for	 de‐
signed time. In the inhibitor test, the PC12 cells were first incubated 
with	4	mL	of	DMEM	medium	containing	an	inhibitor	for	30	minutes	
and then 1 mL of medium with test samples was added. To prepare 
protein lysates, the cells were collected and lysed in lysis buffer. 
After centrifugation at 13 800 g for 15 minutes, the supernatant was 
removed. Protein samples from PC12 cells were treated and ana‐
lysed through electrophoresis as described before.5	Method	details	
for Western blot are presented in supplementary materials.
2.7 | LanthaScreen TR‐FRET competitive 
binding assay
The	LanthaScreen	TR‐FRET	GR	competitive	binding	assay	was	used	
to determine whether CuB was potential GR ligand, and method de‐
tails are presented in supplementary materials.
2.8 | Cellular thermal shift assay
The cellular thermal shift assay was performed as described in other 
reports.15 At first, 2 × 106 cells were separately added into 6‐cm 
dishes	 contained	 5	mL	DMEM	 and	 incubated	 for	 24	 hours.	 After	
that, CuB was added into each plate at the final concentration of 
F I G U R E  1   Neurogenesis effect of 
cucurbitacin B (CuB) on PC12 cells. A, 
Chemical structure of CuB. B, Percentage 
of neurite outgrowth of PC12 cells after 
treatment	with	30,	100	and	300	nM	CuB	
for	48	h.	C‐D,	Morphological	change	and	
percentage of neurite outgrowth of PC12 
cells	treated	with	CuB	and	NGF.	Scale	
bar	is	100	µm.	E,	MTT	assay	result	of	
different doses of CuB and CuB with 3 ng/
mL	NGF	in	PC12	cells.	Each	experiment	
was repeated for three times. The data 
represented	mean	±	SEM.	*P < 0.05, 
**P	<	0.01	and	***P < 0.001 indicated 
significant difference compared with 
the control group; #P < 0.05 indicated 
significant difference compared with 
300	nM	CuB	group;	ns	indicated	no	
significant difference compared with 
40	ng/mL	NGF	group
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0.3	µM.	The	cells	were	collected	after	continual	incubating	0.5	hour	
and heated at different temperatures such as 50, 54, 58 and 62°C. 
Next, Western blot analysis was used to detect the change in cofilin 
protein as described in Western blot.
2.9 | Animal experiments
One hundred male ICR mice (12 weeks old, 40‐45 g) and ten fe‐
male	 ICR	mice	 (8	weeks	old,	25‐30	g)	were	purchased	 from	SLAC	
Laboratory	 Animal	 Company.	 In	 addition,	 fifty	 APP/PS1	 mice	
(4	months)	 and	 thirty	 C57BL/6J	mice	 (4	months)	 were	 purchased	
from	the	Model	Animal	Research	Center	of	Nanjing	University.	Mice	
were housed as five mice per cage, allowed free access to water and 
food, and maintained in constant temperature (23 ± 1°C) and hu‐
midity	 (55%	±	5%)	under	a	12‐hour	 light/dark	cycle	 (lights	on	8:00	
to 20:00). All experiments were conducted in accordance with the 
Committee on Animal Experiments at Zhejiang University (Permit 
ZJU20160236).
2.10 | BrdU or BrdU and NeuN immunostaining in 
ICR mice
To investigate the neurogenesis function of CuB in normal mice, 24 
ICR mice were equally divided into control and CuB 0.02, 0.1 and 
0.5	mg/kg	groups.	CuB	was	dissolved	 in	saline	with	1%	Tween‐80	
and	2%	ethanol.	The	schedule	of	animal	experiment	is	presented	in	
Figure	 S1A.	 In	BrdU	 immunostaining	 test,	 ICR	mice	were	 oral‐ad‐
ministered with vehicle or CuB for 31 consecutive days. Two days 
later,	mice	were	received	four	injections	of	100	mg/kg	BrdU	(Sigma)	
with an interval of 12 hours. At the end of experiment, the mice 
were anaesthetized with chloral hydrate (400 mg/kg, i.p.) and per‐
fused	 transcardially	 with	 4%	 paraformaldehyde.	 Then,	 the	 brains	
were	post‐fixed	for	48	hours	 in	4%	paraformaldehyde,	dehydrated	
for	3	days	 in	30%	sucrose	 solvent	 followed	by	embedded	 in	OCT	
compound	(Sakura	Finetek)	at	−30°C.	Coronally,	slide	was	cut	 into	
50‐μM‐thick	sections	using	a	vibrating	microtome	(Leica	CM1900).	
Sections	were	treated	with	formamide	mixed	with	4×	SSC	buffer	for	
2	hours	at	65°C,	and	then	treated	with	2	M	HCl	for	30	minutes	at	
37°C,	and	0.1	M	boric	acid	(pH	=	8.5)	for	10	minutes	at	room	temper‐
ature, successively. After washing, the sections were treated with 
goat serum for 1 hour, and then incubated with anti‐BrdU antibody 
(Abcam)	 at	4°C	 for	48	hours.	 Finally,	 the	 sections	were	 incubated	
with	CY3‐labelled	 anti‐rat	 IgG	 antibody	 (Millipore)	 in	 the	 dark	 for	
4 hours. Afterwards, they were mounted onto subbed slides and 
cover‐slipped	using	fluoromount	(Sigma).	BrdU	cells	in	bilateral	hip‐
pocampal DG were assessed under a confocal laser‐scanning micro‐
scope	(LSM510;	Zeiss)	at	excitation	of	488	nm.
Based	 on	 the	 result	 in	 Figure	 S1B,	 the	 most	 suitable	 concen‐
tration of CuB is 0.1 mg/kg. Thus, 0.1 mg/kg CuB was used to in‐
vestigate the newborn neurons in ICR mice by BrdU/NeuN double 
immunostaining	as	shown	in	Figure	S1A.	The	protocol	is	similar	with	
BrdU immunostaining test, except that the sections were incubated 
with	both	anti‐BrdU	and	anti‐NeuN	(Millipore)	antibodies	followed	
by incubation with both CY3‐labelled anti‐rat IgG antibody and fluo‐
rescent‐conjugated	antimouse	antibody	(Millipore).
2.11 | Neuroprotection experiment of CuB on the 
APP/PS1 mice
The	neuroprotection	experiment	of	CuB	in	APP/PS1	mice	was	per‐
formed	 as	 presented	 in	 Figure	 S1C.	Mice	were	 divided	 into	 three	
groups:	 (a)	 C57BL/6J	 control;	 (b)	 APP/PS1	 control;	 and	 (c)	 APP/
PS1	 +	 CuB	 (0.1	 mg/kg),	 each	 group	 had	 eight	 mice.	 The	 experi‐
ment included animal behaviour tests and BrdU/NeuN double im‐
munostaining test. Two control groups received vehicle, whereas 
the	 APP/PS1	 +	 CuB	 (0.1	 mg/kg)	 group	 received	 0.1	 mg/kg	 CuB	
for consecutive 31 days. After 2 days of oral administration, mice 
were received four injections of 100 mg/kg BrdU with an interval 
of 12 hours. Then, 19 days later, mice were subjected to the Y‐maze, 
novel	 objects	 recognition	 (NOR)	 and	Morris	 water	 maze	 (MWM).	
Finally,	 the	 brains	 of	mice	were	 obtained	 and	 used	 for	 the	BrdU/
NeuN double immunostaining test, and the method was the same as 
that in the double immunostaining study on ICR mice.
2.12 | Animal behaviour tests
The Y‐maze is a three‐arm maze with equal angles between all arms, 
which were 30 cm long and 5 cm wide with 12‐cm‐high walls. The 
mice were initially placed in one arm and allowed to move freely. The 
sequence and number of arm entries were manually recorded over 
8‐minute periods. Alternation was considered a successive entry 
when the mice entered all three arms successively, that is BCA but 
not	ABA.	The	spontaneous	alternation	(%)	was	defined	as	the	total	
number of alternations divided by the total number of entries.
The apparatus of NOR task contains an open‐field arena of 
40 cm × 25 cm × 20 cm (length × width × height), one novel object 
and two familiar objects. In the first 2 days, mice were placed into the 
apparatus without object for 5 minutes for habituation. The training 
and test sessions started in the third day. In the training session, 
mice were placed in the apparatus containing two familiar objects 
and allowing exploring for 5 minutes. The objects were positioned 
in two adjacent corners, 5 cm from the walls. The test session was 
performed 1 hour after training session, in which one familiar object 
was	replaced	with	a	novel	object.	Mice	were	allowed	to	explore	the	
objects for 5 minutes. Exploration time was defined by directing the 
nose to the object at a distance within 2 cm and/or touching the 
object	with	the	nose	or	forepaws.	The	object	recognition	index	(%)	
was represented with the percentage of exploring time on the novel 
object divided by the total exploring time.
The	MWM	was	performed	as	other	reports,16,17 and the detail 
description is displayed in the supplementary information.
2.13 | Statistical analysis
All experiments were independently performed two or three times, and 
each experiment was conducted using six or eight samples. Data were 
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presented	 as	 mean	 ±	 SEM.	 Significant	 differences	 between	 groups	
were	 determined	 by	 ANOVA,	 followed	 by	 one‐tailed	 Tukey's	multi‐
ple comparison test using GraphPad Prism 5.0 software (GraphPad 
Software).	Statistical	significance	was	considered	at	P < 0.05.
3  | RESULTS
3.1 | CuB increases neurite outgrowth and length in 
PC12 cells and primary neuron cells in vitro
The neurogenesis effect of CuB was first confirmed in PC12 cells in 
vitro. Cells were treated with CuB at various concentrations of 30, 100 
and	300	nM	for	48	hours.	CuB	from	30	to	300	nM	could	dose‐depend‐
ently	increase	neurite	outgrowth	and	length	in	PC12	cells	(Figure	1B	
and	Figure	S2A,	P < 0.01, P < 0.001, P < 0.001). Interestingly, CuB‐
combined	NGF	could	markedly	increase	the	percentage	of	PC12	cells	
with	neurite	outgrowth	from	48.5	±	3.5%	to	80.0	±	2.0%	(Figure	1C‐D)	
and neurite length of PC12 cells from 335.3 ± 28.8 to 420.9 ± 28.5 µm 
(Figure	S2B).	These	data	indicate	that	CuB	exhibits	a	novel	NGF‐mimic	
and	NGF‐enhancer	ability	in	PC12	cells.	To	evaluate	the	cytotoxicity	
of	CuB	at	the	cellular	level,	MTT	assay	was	conducted.	The	viabilities	
of	PC12	cells	were	78.7	±	10.3%,	69.4	±	1.4%	and	62.6	±	2.5%	after	
treating	CuB	at	doses	of	30,	100	and	300	nM	(P < 0.05, P < 0.01), re‐
spectively. These results indicate that CuB has cytotoxic to PC12 cells. 
However,	the	viability	of	PC12	cells	in	300	nM	CuB‐treated	group	was	
significantly	increased	to	86.9	±	2.5%	after	adding	NGF	at	a	dose	of	
3 ng/mL (P	<	0.05).	This	result	suggests	that	low‐dose	NGF	can	lower	
the toxicity of CuB.
The neurogenesis effect of CuB was then estimated in primary 
neuron	cells.	As	shown	in	Figure	2A,	the	neurite	outgrowth	of	pri‐
mary	 neuron	 cell	 treatment	with	0.3	 nM	CuB	with/without	 1	 ng/
mL	NGF	for	72	hours	significantly	increased.	The	average	of	neurite	
length and primary dendrite number in each group is displayed in 
Figure	2B‐C.	CuB	at	0.3	nM	markedly	increased	the	neurite	length	
of primary neuron cells from 40.1 ± 3.1 to 53.5 ± 3.8 µm and primary 
dendrite number from 2.7 ± 0.1 to 3.4 ± 0.2 (P < 0.01, P < 0.001). 
Moreover,	0.3	nM	CuB‐combined	1	ng/mL	NGF	increased	the	neu‐
rogenesis	effect	to	a	 level	comparable	with	that	of	10	ng/mL	NGF	
(P < 0.001, P < 0.001). Collectively, these results suggest that CuB 
exerts a neurogenesis effect not only in PC12 cells but also in pri‐
mary cortical neuron cells.
3.2 | CuB increases newborn neurons of the 
hippocampus in ICR and APP/PS1 mice and rescues 
working memory in APP/PS1 mice
The neurogenesis effect of CuB was further assessed in ICR nor‐
mal	 mice	 in	 vivo.	 First,	 we	 did	 an	 experiment	 to	 confirm	 suitable	
F I G U R E  2   Neurogenesis effect of 
cucurbitacin B (CuB) on primary neuron 
cells.	A,	Morphological	changes	in	primary	
neuron cells after treatment with agents 
for	72	h:	(1)	control	(0.5%	DMSO),	(2)	
positive	control	(NGF	10	ng/mL),	(3)	NGF	
1	ng/mL,	(4)	CuB	0.1	nM,	(5)	CuB	0.3	nM	
and	(6)	CuB	0.3	nM	+	NGF	1	ng/mL.	Scale	
bar is 20 µm. B‐C, The average of neurite 
length and primary dendrite number in 
each	group.	For	each	result,	60	cells	were	
counted. This experiment was repeated 
for three times. The data represented 
mean	±	SEM.	**P	<	0.01,	***P < 0.001 
indicated significant difference compared 
with the control group
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concentration	of	CuB.	Result	in	Figure	S1B	illustrated	that	the	numbers	
of juvenile cells in the hippocampal DG zone of CuB 0.1 and 0.5 mg/
kg groups were markedly increased compared with the control mice 
(P < 0.05, P < 0.05). Considering the security, we used 0.1 mg/kg CuB 
to perform the BrdU/NeuN double stain. The total number of 28‐day‐
old BrdU/NeuN cells in 0.1 mg/kg CuB group was significantly higher 
than that in the control group (P	<	0.001,	Figure	3A).	These	results	
imply that CuB can increase juvenile cells and newly differentiated 
neuron cells in the hippocampus of normal mice.
The neurogenesis and neuroprotection effects of CuB were fur‐
ther	studied	on	APP/PS1	mice,	an	AD	model	mouse	with	the	method	
shown	in	Figure	S1C.	The	total	number	of	newly	differentiated	neu‐
ron cells in 0.1 mg/kg CuB group was significantly increased com‐
pared	with	APP/PS1	control	group,	as	shown	in	Figure	3B	(P < 0.05). 
Furthermore,	 animal	behaviour	 tests	were	performed,	 and	 the	 re‐
sults	 are	presented	 in	Figure	3C‐H.	 In	 the	Y‐maze	 test,	 no	 signifi‐
cant differences in the number of arm entries were observed among 
these	three	groups	(Figure	3C).	The	spontaneous	alternation	in	the	
APP/PS1	group	(58.9	±	3.9%)	was	significantly	decreased	compared	
with	the	C57BL/6J	group	(71.5	±	3.6%)	(Figure	3D,	P < 0.01). CuB at 
0.1 mg/kg significantly improved spontaneous alternation in APP/
PS1	mice	to	67.2	±	2.7%	 (Figure	3D,	P	<	0.05).	Furthermore,	NOR	
was performed to evaluate the memory. The total time spent on the 
object on training and test sessions of the three groups showed no 
significant	differences	(Figure	3E).	However,	in	the	test	session,	the	
object	 recognition	 index	of	C57BL/6J	 control	 group	 (66.5	±	5.9%)	
and	CuB	+	APP/PS1	group	(65.0	±	6.1%)	was	significantly	higher	than	
that	of	the	APP/PS1	group	(54.0	±	4.4%)	(Figure	3F).	However,	in	the	
WMM,	the	treatment	of	CuB	did	not	ameliorate	the	long‐term	mem‐
ory	 deficit	 of	 APP/PS1	mice	 (Figure	 3G‐H).	 These	 results	 suggest	
that CuB can improve the working memory but not the long‐term 
memory	of	APP/PS1	mice.
3.3 | CuB could modulate the GR/phospholipase 
C (PLC)/protein kinase C (PKC) and GR/ERK 
signalling pathway
Glucocorticoid receptor is involved in regulating neuronal struc‐
ture and plasticity.18 Thus, the GR inhibitor RU486 was first used 
to illuminate the mechanism of CuB in PC12 cells. RU486 could sig‐
nificantly attenuate the percentage of PC12 cells with neurite out‐
growth	 induced	by	300	nM	CuB	 from	 initial	 value	of	41.5	±	3.5%	
to	17.7	±	0.9%	and	shorted	the	 lengths	 (Figure	4A	and	Figure	S3).	
Meanwhile,	 as	PLC/PKC	 is	 located	downstream	of	GR,	 the	 signal‐
ling is critical for the survival of sympathetic neurons.19,20 The spe‐
cific PLC inhibitor U73343 and PKC inhibitor GO6983 were used 
to examine the effects of CuB on the PLC/PKC signalling pathway. 
The neurite outgrowth of PC12 cells induced by treatment with CuB 
and	 CuB‐combined	 NGF	 was	 markedly	 reduced	 by	 U73343	 and	
GO6983	(Figure	4B‐C,	P < 0.001, P < 0.001, P < 0.001, P < 0.001). 
F I G U R E  3  Neurogenesis	effect	of	cucurbitacin	B	(CuB)	on	ICR	and	APP/PS1	mice.	A‐B,	Fluorescent	immunohistochemistry	image	
of	28‐day‐old	newborn	mature	neurons	stained	with	a	BrdU	antibody	(red)	and	a	NeuN	antibody	(green)	of	ICR	and	APP/PS1	mice,	
separately	(n	=	6).	Scale	bar	is	50	µm.	Bar	graph	showed	the	number	of	BrdU	and	NeuN	double‐labelled	cells.	C‐D,	The	total	arm	entries	and	
spontaneous	alternation	in	Y‐maze	test.	E‐F,	Time	spent	on	object	and	object	recognition	index	in	NOR	test	(n	=	8).	G‐H,	the	escape	latency	
and	the	number	of	crossing	platform	at	day	5	in	water	maze	experiment.	The	data	represented	mean	±	SEM.	*P	<	0.05,	**P < 0.01 and 
***P < 0.001 indicated significant difference compared with the control group; #P < 0.05 indicated significant difference compared with the 
APP/PS1	control	group;	$$$P < 0.001 indicated significant difference between training and test sessions
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F I G U R E  4   Effects of cucurbitacin B (CuB) on GR/PLC/PKC signalling pathway in PC12 cells. A‐C, Effects of GR inhibitor RU486, PLC 
inhibitor U73343 and PKC inhibitor GO6983 on CuB‐induced neurite outgrowth on PC12 cells. D, CuB stimulated the phosphorylation 
of GR, PLC‐γ1 and PKC in a time‐dependent manner. E, CuB stimulated the phosphorylation of GR and ERK (the cells were treated with 
each	agent	for	1	h),	and	GR	inhibitor	RU486	decreased	the	protein	level	of	phosphorylation	of	GR	and	ERK	in	PC12	cells.	F,	PLCγ1 inhibitor 
U73343 attenuated the phosphorylation of PLCγ1 induced by CuB in PC12 cells (the cells treated with each agent for 16 h). G, PKC inhibitor 
GO6983 attenuated the phosphorylation of PKC induced by CuB in PC12 cells (the cells treated with each agent for 16 h). Each experiment 
was	repeated	for	three	times.	The	data	represented	mean	±	SEM.	*P	<	0.05,	**P	<	0.01	and	***P < 0.001 indicated significant difference 
compared with the control group; #P < 0.05, ##P < 0.01 and ###P < 0.001 indicated significant difference compared with CuB or CuB with 
NGF	group
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Subsequently,	the	phosphorylation	of	GR,	PLC‐γ1 and PKC induced 
by	 300	 nM	CuB	 at	 the	 protein	 level	 was	 investigated	 at	 multiple	
time points. The phosphorylation of GR protein was first increased, 
peaked	at	1	hour	and	then	decreased	after	8	hours	(Figure	4D).	The	
phosphorylation	levels	of	PKC	and	PLC	induced	by	300	nM	CuB	were	
initiated	at	8	hours	and	then	maintained	for	48	hours	 (Figure	4D).	
Furthermore,	 the	 increase	 in	 GR	 and	 ERK	 phosphorylation	 in	 the	
300	nM	CuB	with/without	 3	 ng/mL	NGF	groups	 could	 be	 signifi‐
cantly	reduced	by	RU486	(Figure	4E	and	Figure	S7B).	A	binding	assay	
was carried out to determine whether CuB was potential GR ligand. 
However, the result showed that GR protein was not the target of 
CuB	(Figure	S4).	Moreover,	the	phosphorylation	of	PLC‐γ1 and PKC 
in	the	40	ng/mL	NGF,	300	nM	CuB	and	300	nM	CuB	combined	3	ng/
mL	 NGF	 groups	 was	 significantly	 decreased	 after	 treatment	 with	
U73343	and	GO6983	(Figure	4F‐G	and	Figure	S7C‐D).	These	results	
suggest that GR/PLC‐γ1/PKC signalling pathway is involved in the 
CuB‐induced neuronal differentiation of PC12 cells.
3.4 | CuB could modulate the cofilin and actin 
signalling pathway
Considering	that	the	GR	protein	is	not	the	target	of	CuB	(Figure	S4),	
we performed a hierarchical cluster analysis in HeLa cells to predict 
the	probable	target	of	CuB.	The	results	are	displayed	 in	Figure	5A.	
F I G U R E  5   ChemProteoBase profiling result of cucurbitacin B (CuB) on HeLa cells and effect of CuB on the cofilin protein on PC12 cells. 
A, Hierarchical clustering of CuB and 41 well‐characterized compounds in ChemProteoBase was performed. B, Cosine similarity between 
CuB and compounds in ChemProteoBase was calculated, and top 10 compounds similar to CuB in ranking are shown. C, The protein‐level 
changes in p‐cofilin, cofilin and β‐actin	after	treatment	with	CuB	at	a	dose	of	300	nM	for	48	h	in	PC12	cells.	D,	The	protein‐level	changes	
in p‐cofilin, cofilin and β‐actin	after	treatment	with	CuB	at	0,	0.003,	0.03,	0.3,	3	and	30	µM	for	30	min.	E,	The	correlation	of	binding	ability	
between	CuB	and	cofilin	protein	at	50,	54,	58	and	62°C.	The	cells	were	treated	with	300	nM	CuB	for	0.5	h.	Each	experiment	was	repeated	
for	three	times.	The	data	represented	mean	±	SEM.	*P	<	0.001	and	***P < 0.001 indicated significant difference compared with the control 
group
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The top 10 compounds in the ChemProteoBase are provided in 
Figure	5B.	Compounds	similar	to	CuB	were	not	found	in	the	data	set,	
but compounds that ranked second or third were actin inhibitors, cy‐
tochalasin D (actin depolymerizer) and jasplakinolide (actin stabilizer). 
Some	spots	of	actin	significantly	increased	in	the	CuB‐treated	HeLa	
cells.	Similarly,	previous	studies	reported	that	CuB	could	bind	to	co‐
filin, inducing cofilin hyperactivation and actin aggregation.21 Thus, 
the change in cofilin phosphorylation after adding CuB was inves‐
tigated in PC12 cells. As expected, cofilin phosphorylation in CuB‐
treated group was significantly decreased from 0.5 hour and lasted 
for	48	hours	with	increase	in	incubation	time.	Furthermore,	the	phos‐
phorylation of cofilin was dose‐dependently decreased after adding 
CuB at doses of 0.003, 0.03, 0.3 and 3 to 30 μM	(Figure	5C‐D	and	
Figure	S7E‐F).	To	confirm	that	if	there	was	a	binding	correlation	be‐
tween	CuB	and	cofilin	protein,	we	performed	CETSA	using	PC12	cell	
lines. As the temperature increase, the protein level of cofilin in CuB‐
treated group was significantly higher than that of control group at 58 
and	62°C	(Figure	5E	and	Figure	S7G,	P < 0.05, P < 0.001). Therefore, 
these results further indicated that cofilin was targeting protein of 
CuB	to	produce	NGF	mimic	and	enhancer	effects	in	PC12	cells.
3.5 | CuB could modulate the TrkA/Ras/Raf/ERK 
signalling pathway
TrkA	could	be	stimulated	by	NGF	in	PC12	cells	and	lead	to	the	forma‐
tion of signalling endosomes.22 Thus, we examined whether the TrkA 
signalling	pathway	was	taken	part	 in	 the	NGF	mimic	effect	of	CuB.	
The specific inhibitor of TrkA (K252a) could significantly attenuate the 
percentage of neurite outgrowth of PC12 cells induced by CuB from 
45.0	±	2.9%	to	12.5	±	1.5%	and	the	neurite	length	of	PC12	cells	from	
180.1	±	14.6	to	100.1	±	12.9	µm	(Figure	6A	and	Figure	S5,	P < 0.001, 
P	 <	 0.001).	 Similarly,	 K252a	 could	 decrease	 the	 neurite	 length	 and	
outgrowth	of	CuB‐combined	NGF	group	(P	<	0.001).	Several	signalling	
cascades initiated by TrkA receptor activation, including the Ras/Raf/
ERK	pathway,	have	been	implicated	in	the	NGF‐induced	differentia‐
tion of PC12 cells.22 Thus, the effect of CuB on the Ras/Raf/ERK sig‐
nalling	pathway	was	investigated.	As	displayed	in	Figure	6B	and	Figure	
S6B‐C,	the	addition	of	Ras	inhibitor	(S3131),	Raf	inhibitor	(AZ628)	and	
ERK inhibitor (U0126) markedly reduced the percentage of neurite 
outgrowth	of	PC12	cells	induced	by	CuB	and	CuB‐combined	NGF	at	
48	hours,	respectively.	Furthermore,	Ras	mutant	type	of	PC12	cells	
was used to detect the effect of CuB on Ras protein. CuB did not ex‐
hibit	neurogenesis	ability	in	Ras	mutant	PC12	cells	(Figure	6C).
Then, the effects of CuB on TrkA/Ras/Raf/ERK phosphorylation 
were investigated at protein level. TrkA phosphorylation was signifi‐
cantly	increased	after	treating	CuB	for	30	minutes	(Figure	6D).	The	in‐
crease in ERK and CREB phosphorylation induced by CuB was begun 
at	8	hours	and	maintained	for	48	hours	(Figure	6D).	Meanwhile,	K252a	
at 0.1 μM	 could	 significantly	 decrease	 the	 TrkA	 phosphorylation	 in	
CuB‐treated	groups	and	NGF‐treated	group	(Figure	6E	and	Figure	S7I).	
However, the TrkB inhibitor ANA‐12 could not decrease the percentage 
of	neurite	outgrowth	caused	by	CuB	(Figure	S6A).	ERK	phosphoryla‐
tion	in	CuB	and	CuB‐combined	low‐dose	NGF	groups	was	significantly	
decreased	 after	 treatment	with	U0126	 for	 16	 hours	 (Figure	 6F	 and	
Figure	S7J).	These	results	demonstrate	 that	TrkA/Ras/Raf/ERK	plays	
an important role on CuB‐induced neurite outgrowth on PC12 cells.
4  | DISCUSSION
Cucurbitacin B has long been used as a liver protectant in China. 
A large number of studies have focused on its anti‐inflammatory, 
antioxidant, antiviral, antipyretic, analgesic and anti‐malaria ac‐
tivities.8 In the current study, we provided evidence in PC12 cells 
(Figure	 1),	 primary	 neuron	 cells	 (Figure	 2),	 ICR	mice	 and	APP/PS1	
mice	(Figure	3A‐B)	that	CuB	also	exhibits	a	neurogenesis	function.	
Furthermore,	animal	behaviour	tests	showed	that	CuB	could	improve	
memory	 in	 APP/PS1	mice	 (Figure	 3C‐F).	 Unlike	 the	most	 popular	
acetylcholinesterase inhibitor anti‐AD drugs, CuB could ameliorate 
the memory deficits associated with enhanced neurogenesis.
Neuron loss is an important symptom of AD and is the main 
course of studying ability decline. Researchers found that increased 
newborn mature neuron might be a valuable method to improve 
learning and memory.23 In the present study, the memory protection 
effect of CuB on AD model mice was tested using Y‐maze, NOR and 
Morris	water	maze.	Consistent	with	our	inference,	the	results	of	Y‐
maze and NOR tests showed that CuB could improve the working 
memory	of	AD	mice	(Figure	3C‐F).	However,	CuB	did	not	ameliorate	
long‐term	memory	in	the	Morris	water	maze	(Figure	3G‐H).	At	this	
point, the memory protective effect of CuB might only occur in the 
regulation of working memory but not long‐term memory.
The	signalling	pathways	of	CuB,	including	JAK2/STAT3,	cofilin,	
cyclins	and	MAPK/ERK,	have	been	reported.8,24,25 Glucocorticoids 
(GCs) can induce significant changes in the function of both neu‐
ronal and non‐neuronal cells. GCs can affect the structure and 
function	 of	 the	 CNS,	 especially	 those	 of	 the	 hippocampus.26,27 
In PC12 cells, GR is profoundly affected by neurite outgrowth 
and neurons.18 In the current study, CuB could modulate the GR/
PLC/PKC	 and	 GR/ERK	 signalling	 pathways	 (Figure	 4).	 However,	
the	results	of	LanthaScreen™	TR‐FRET	competitive	binding	assay	
showed	 that	 GR	 was	 not	 the	 direct	 target	 of	 CuB	 (Figure	 S4).	
Thus, hierarchical cluster analysis, a target prediction experiment, 
was conducted in HeLa cells to find the potential target of CuB 
(Figure	5).	Results	revealed	that	CuB	could	affect	actin	dynamics	
as an actin inhibitor in HeLa cells. However, several researchers 
found that the CuB‐induced actin aggregation by the formation of 
cofilin‐actin rods depended on cofilin hyperactivation.28 Cofilin, 
an	actin‐depolymerizing	factor,	can	sever	actin	filaments	(F‐actin)	
when it is activated through dephosphorylation at the conserved 
serine residue 3.29 Thus, Western blot was performed to check 
the change in the upstream signalling pathway of actin in PC12 
cells.	 Results	 in	 Figure	 5C	 demonstrated	 that	 cofilin	was	 hyper‐
activated by CuB in a time‐ and dose‐dependent manner, which 
agreed with the results of a previous study using A375 cells.28 We 
demonstrated that cofilin hyperactivation might be related to the 
events	of	CuB‐induced	actin	aggregation.	Furthermore,	we	used	
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the	CESTA	to	investigate	the	correlation	between	cofilin	and	CuB.	
The	result	 in	Figure	5E	 indicated	that	cofilin	might	be	the	target	
protein of CuB to produce neurogenesis effect.
In the present study, we found that CuB could significantly 
increase the phosphorylation of PLC‐γ1 and dephosphorylation 
of	 cofilin	 to	 produce	 NGF	 mimic	 and	 enhancer	 effects	 in	 PC12	
F I G U R E  6   Effects of cucurbitacin B (CuB) on TrkA/ERK signalling pathway on PC12 cells. A‐B, Effects of TrkA inhibitor K252a, and ERK 
inhibitor U0126 on CuB‐induced neurite outgrowth on PC12 cells. C, The percentage of neurite outgrowth in wide‐type or Ras mutant‐type 
PC12 cells induced by CuB for 48 h. D, CuB stimulated the phosphorylation of TrkA, ERK and CREB in a time‐dependent manner. E, CuB 
stimulated the phosphorylation of TrkA (the cells were treated with each agent for 30 min) and inhibitor K252a decreased the protein level 
of	phosphorylation	of	TrkA	in	PC12	cells.	F,	ERK	inhibitor	U0126	attenuated	the	phosphorylation	of	ERK	induced	by	CuB	in	PC12	cells	
(the	cells	treated	with	each	agent	for	16	h).	Each	experiment	was	repeated	for	three	times.	The	data	represented	mean	±	SEM.	*P < 0.05, 
**P	<	0.01	and	***P < 0.001 indicated significant difference compared with the control group; #P < 0.05, ##P < 0.01 and ###P < 0.001 
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cells. Recently, some evidence also indicated that PLC‐γ1 signal‐
ling could regulate the localization of the actin‐depolymerizing and 
actin‐severing factor cofilin in the maintenance of dendritic spine 
morphology in brain,30 and its inhibitor U73122 could block the de‐
phosphorylation and translocation of cofilin.31 This evidence sup‐
ported our results which the interaction of PLCγ1 and cofilin took 
important	roles	during	CuB	produced	NGF	mimic	and	enhancer.
Some	studies	 suggest	 that	aside	 from	 the	GR	and	cofilin	 signal‐
ling cascades, the TrkA/ERK pathway also affects differentiation.32 
Therefore, we investigated the possible involvement of the TrkA/
ERK	 pathway	 in	 regulating	 the	 NGF‐mimic	 effects	 of	 CuB.	 Results	
in	Figure	6	 suggested	 that	TrkA	also	 contributes	 to	 the	NGF‐mimic	
effects	of	CuB.	Meanwhile,	Ras	mutant	PC12	cells	could	 inhibit	 the	
differentiation	of	PC12	cells	 induced	by	CuB	 (Figure	6C).	These	 re‐
sults	 suggest	 that	 the	NGF‐mimic	effects	of	CuB	on	PC12	cells	are	
mediated by TrkA receptor, and these effects activate ERK and CREB 
signalling cascades to induce neurogenic activities. TrkB was also in‐
vestigated but was found to be not involved in CuB‐initiated cascades 
(Figure	S6A).	Notably,	a	major	contribution	of	GR	significantly	induced	
ERK	phosphorylation	(Figure	4D),	which	was	similar	to	a	part	of	the	
TrkA signalling pathway. Thus, we inferred that several signalling path‐
ways	participate	in	the	regulation	of	the	NGF‐mimic	effects	of	CuB.
In the current study, we confirmed that the neurogenesis effect of 
CuB was related to TrkA and GR. Interestingly, we found that several 
different type compounds could induce neurogenic activities through 
different signalling pathways such as tetradecyl 2,3‐dihydroxybenzo‐
ate and Lindersin B.12,32 Lindersin B could induce neurite outgrowth via 
the TrkA signalling pathway. However, tetradecyl 2,3‐dihydroxybenzo‐
ate	showed	neuroprotective	effect	on	PC12	cells	by	 IGF‐1	receptor.	
Considering all of these results, we speculate that using a mixture of 
small molecules with different targets might strikingly increase the 
neurogenesis effect in PC12 cells, which is worth further studying.
In summary, CuB can enhance neurogenesis in vitro and in vivo and 
ameliorate	the	working	memory	of	APP/PS1	mice.	In	PC12	cells,	cofilin	
might be the candidate target of CuB, and the GR/PLC/PKC and TrkA/
Ras/Raf/ERK signalling pathways play important roles in the neuroprotec‐
tion	of	CuB	(Figure	7).	As	CuB	is	already	in	clinical	use,	it	could	be	a	novel	
therapeutic	for	Alzheimerr's	disease.	Further	work	is	warranted	to	reveal	
the direct target(s) of CuB, which may ultimately explain its mechanism.
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